Cost-Sharing and Buprenorphine Prescription Dispensing
Thuy D. Nguyen, Rena M. Conti, Pooja Lagisetty, Amy S. B. Bohnert, Ushapoorna Nuliyalu, Kao-Ping Chua
TL;DR
This study examines how out-of-pocket costs affect the dispensing of buprenorphine, a medication used for opioid use disorder, among patients with commercial and Medicare insurance.
Contribution
The study provides new evidence on how cost-sharing impacts buprenorphine prescription dispensing in different insurance groups.
Findings
Higher cost-sharing is associated with lower rates of buprenorphine dispensing.
The effect of cost-sharing on dispensing varies between commercially insured and Medicare-insured patients.
Abstract
This cross-sectional study estimates the association between cost-sharing and buprenorphine dispensing among commercially insured and Medicare-insured patients.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsOpioid Use Disorder Treatment · Healthcare Policy and Management · Taxation and Compliance Studies